Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 22;12:641206. doi: 10.3389/fimmu.2021.641206

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 He, Hung, Liang, Zhang, Gao, Chu, Zhang, Xu, Chung and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

MDSC subsets in peritoneal blood, bone marrow, and peripheral fluid after Sunitinib treatment. (A–C) G-MDSC (defined as CD11b⁺ Ly6G⁺ Ly6C^lo) and M-MDSC (defined as CD11b⁺ Ly6G^- Ly6C^hi) percentage in peripheral blood 1 day before as baseline (day -1), after 1 day (day 1) and 7 days (day 7) of control and Sunitinib treatment. (D, E) G-MDSC and M-MDSC percentage in the bone marrow and peritoneal fluid after 7 days of treatment. (F) Percentage of P-STAT3 in peritoneal G-MDSC and M-MDSC after 7 days of treatment. (G) Representative flow cytometric analyses of intracellular levels of p-Stat3 in peritoneal MDSCs. Data are expressed as the mean ± SEM from 5 animals in each group, *p < 0.05.